- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770523
Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells
June 8, 2011 updated by: Cooperative Study Group A for Hematology
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients with Hematologic Malignancies.
Study Overview
Status
Completed
Conditions
Detailed Description
Primary end points are treatment-related mortality and engraftment.
Secondary end points are regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.
Study Type
Observational
Enrollment (Actual)
52
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 55 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
acute leukemia chronic myelogenous leukemia myelodysplastic syndrome
Description
Inclusion Criteria:
-Patients should have an unrelated donor who is matched for HLA-A and -B by serology and for -DRB1 by molecular typing.
Exclusion Criteria:
- Patients should not have major illness or organ failure
- Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible.
- Patients must not be pregnant or lactating.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
treatment-related mortality and engraftment
Time Frame: all cause mortality
|
all cause mortality
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.
Time Frame: Time point(s) at which outcome measure is assessed.
|
Time point(s) at which outcome measure is assessed.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kyoo-hyung Lee, doctor, COSAH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2003
Primary Completion (Actual)
March 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
October 5, 2008
First Submitted That Met QC Criteria
October 9, 2008
First Posted (Estimate)
October 10, 2008
Study Record Updates
Last Update Posted (Estimate)
June 10, 2011
Last Update Submitted That Met QC Criteria
June 8, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HEMATOLOGIC MALIGNANCIES
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Washington University School of MedicineRecruitingPediatric Hematologic MalignanciesUnited States
-
Medical College of WisconsinCompletedMalignancies, HematologicUnited States
-
Sinocelltech Ltd.RecruitingRelapsed or Refractory Hematologic MalignanciesChina
-
Vanda PharmaceuticalsUnknownRelapsed or Refractory Hematologic MalignanciesUnited States
-
Precision BioSciences, Inc.RecruitingHematologic Malignancy | CD19 Expressing MalignanciesUnited States
-
University of UtahTerminatedHigh Risk Hematologic MalignanciesUnited States
-
King Faisal Specialist Hospital & Research CenterCompletedTransplantation for Hematologic MalignanciesSaudi Arabia
-
Constellation PharmaceuticalsNot yet recruitingSolid Tumor | Hematologic Malignancy | Advanced Malignancies
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingAdvanced Solid Tumors and Hematologic MalignanciesChina